U.S. Markets closed

Conversion Labs, Inc. (CVLB)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.2950+0.1150 (+9.75%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1800
Open1.2100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.1800 - 1.3600
52 Week Range0.1000 - 1.3600
Volume718,602
Avg. Volume484,915
Market Cap85.565M
Beta (5Y Monthly)2.20
PE Ratio (TTM)N/A
EPS (TTM)-0.1010
Earnings DateMay 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    LD Micro - Announces Preliminary List of Presenters for the LD-500

    LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

  • GlobeNewswire

    Conversion Labs July 2020 Revenues up 302% to Record $3.6 Million, Remains on Track to Exceed $40 Million in Revenue in 2020

    NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, reported record revenues of $3.6 million in the month of July, up more than 302% versus July 2019.For July 2020, $1.2 million was attributed to recurring revenue from rebilled subscriptions to products and services, up 362% versus July 2019.  “Revenue, and particularly recurring subscription revenue, has grown across the board due to the strategic investments we’ve made in our brands, our people and our digital health platform,” commented Justin Schreiber, CEO of Conversion Labs.“When we connect with a customer seeking treatment, it usually represents the beginning of a long-term relationship between provider and patient,” continued Schreiber. “Our goal is to do everything possible to deliver great ongoing medical care.“As we do a good job with this, we expect our subscription revenue to increase because our patients will continue to turn to us for their medical needs. So, as our telemedicine business grows, we expect our subscription-based revenue to grow accordingly and become an increasingly greater portion of our overall sales.”Conversion Labs’ July results indicate an annualized revenue run-rate of $42.7 million, compared to revenue of $12.5 million for all of 2019—a difference of 242%.Conversion Labs’ CFO, Juan Manuel Piñeiro Dagnery, commented: “Our business strategy has been more than simply about increasing sales and generating profits. We have been primarily focused on building a portfolio of telemedicine brands that can provide a predictable and reliable recurring revenue stream. As the revenue generated by our repeat customers continues to scale and drive down customer acquisition cost as a percentage of revenue, we expect this to drive strong growth in our bottom line over the long term.”According to analysts at Forrester Research, the adoption of telemedicine across the healthcare industry has “shifted into hyper-drive,” with virtual health care visits on pace to top 1 billion by year end. Another recent report projects the global telemedicine market to expand at a rapid 19.3% compounded annual growth rate to reach $175 billion by 2026.Conversion Labs’ new cloud-based, end-to-end telemedicine platform, Veritas MD, addresses this fast growing market, and supports the continued market expansion of the company’s telemedicine brands.“Conversion Labs and its brands have emerged on the forefront of the new telemedicine boom, thanks to our highly effective online marketing program and now our new Veritas MD telemedicine platform,” noted Conversion Labs’ CTO and COO, Stefan Galluppi.“Veritas MD has been designed to connect state-licensed physicians with patients in a simple and efficient manner,” said Galluppi. “This takes the friction out of the healthcare process, making it easier than ever before for physicians to consult with patients and provide the personal care they need. While our growth in rebilled subscriptions has been tremendous, we believe we have only begun to scratch the surface of what Conversion Labs can accomplish.”Conversion Labs recently reported preliminary unaudited results for the second quarter ended June 30, 2020, with revenue reaching a record $9.2 million, up 114% sequentially and up 241% from the same year-ago quarter. As a result, management increased its full-year 2020 revenue outlook from $36 million to more than $40 million. The company has announced it will host an investor call to discuss the second quarter 2020 results at 1 p.m. Eastern time on August 17, 2020.  About Conversion Labs Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.Important Cautions Regarding Forward-Looking Statements   This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.Trademarks are the property of their respective owners.Company Contact Conversion Labs Juan Manuel Piñeiro Dagnery CFO Email ContactMedia and Investor Relations Contact Ron Both or Grant Stude CMA Investor Relations Tel (949) 432-7566 Email Contact

  • GlobeNewswire

    Conversion Labs to Host Second Quarter Conference Call on Monday, August 17, 2020 at 1:00 p.m. ET

    NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, will hold a conference call on Monday, August 17, 2020 at 1:00 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2020. The financial results will be issued in a press release prior to the call. Conversion Labs management will host the conference call followed by a question and answer period.Date: Monday, August 17, 2020 Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time) Toll-free dial-in number: 1-800-437-2398 International dial-in number: 1-720-452-9102 Conference ID: 6173273The conference call will be webcast live and available for replay here as well as via a link in the Investors section of the company’s website at ir.conversionlabs.com.Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.A replay of the call will be available after 4:00 p.m. Eastern time on the same day through August 31, 2020.Toll-free replay number: 1-844-512-2921 International replay number: 1-412-317-6671 Replay ID: 6173273About Conversion Labs Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.Company Contact Conversion Labs Juan Manuel Piñeiro Dagnery CFO Email ContactMedia and Investor Relations Contact Ron Both or Grant Stude CMA Investor Relations Tel (949) 432-7566 Email Contact